<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title xml:lang="eng">CDK6 Degradation Is Counteracted by p16INK4A and p18INK4C in AML</dc:title>
  <dc:date>2022</dc:date>
  <dc:subject xml:lang="eng">Cell-Cycle; Inhibition; Program</dc:subject>
  <dc:rights>CC BY 4.0 International</dc:rights>
  <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
  <dc:identifier>doi:10.3390/cancers14061554</dc:identifier>
  <dc:identifier>https://phaidra.vetmeduni.ac.at/o:1891</dc:identifier>
  <dc:format>application/pdf</dc:format>
  <dc:type xml:lang="eng">article</dc:type>
  <dc:source>Cancers 14(6) (2022)</dc:source>
  <dc:publisher>MDPI</dc:publisher>
  <dc:description xml:lang="eng">Cyclin-dependent kinase 6 (CDK6) represents a novel therapeutic target for the treatment of certain subtypes of acute myeloid leukaemia (AML). CDK4/6 kinase inhibitors have been widely studied in many cancer types and their effects may be limited by primary and secondary resistance mechanisms. CDK4/6 degraders, which eliminate kinase-dependent and kinase-independent effects, have been suggested as an alternative therapeutic option. We show that the efficacy of the CDK6-specific protein degrader BSJ-03-123 varies among AML subtypes and depends on the low expression of the INK4 proteins p16INK4A and p18INK4C. INK4 protein levels are significantly elevated in KMT2A-MLLT3+ cells compared to RUNX1-RUNX1T1+ cells, contributing to the different CDK6 degradation efficacy. We demonstrate that CDK6 complexes containing p16INK4A or p18INK4C are protected from BSJ-mediated degradation and that INK4 levels define the proliferative response to CDK6 degradation. These findings define INK4 proteins as predictive markers for CDK6 degradation-targeted therapies in AML.</dc:description>
  <dc:language>eng</dc:language>
  <dc:creator>Schmalzbauer, Belinda S. (University of Veterinary Medicine Vienna)</dc:creator>
  <dc:creator>Kollmann, Karoline (University of Veterinary Medicine Vienna)</dc:creator>
  <dc:creator>Sperl, Clio-Melina (University of Veterinary Medicine Vienna)</dc:creator>
  <dc:creator>Schirripa, Alessia (University of Veterinary Medicine Vienna)</dc:creator>
  <dc:creator>Thondanpallil, Teresemary (University of Veterinary Medicine Vienna)</dc:creator>
  <dc:creator>Heller, Gerwin (Medical University of Vienna)</dc:creator>
  <dc:creator>Sexl, Veronika (University of Veterinary Medicine Vienna)</dc:creator>
  <dc:creator>Klampfl, Thorsten (University of Veterinary Medicine Vienna)</dc:creator>
  <dc:creator>Fontaine, Frédéric (CeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences)</dc:creator>
  <dc:creator>Mueller, André C. (CeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences)</dc:creator>
  <dc:creator>Zojer, Markus (University of Veterinary Medicine Vienna)</dc:creator>
  <dc:creator>Nebenfuehr, Sofie (University of Veterinary Medicine Vienna)</dc:creator>
  <dc:creator>Knab, Vanessa M. (University of Veterinary Medicine Vienna)</dc:creator>
  <dc:creator>Mayer, Isabella M. (University of Veterinary Medicine Vienna)</dc:creator>
</oai_dc:dc>